About Haleon plc (HLN)
Haleon plc is a Drug Manufacturers - Specialty & Generic company operating in the Healthcare sector. The company is headquartered in Weybridge, United Kingdom. HLN has been publicly traded since 2022, giving it 4+ years of trading history.
Haleon plc (HLN) has been publicly traded since 2022, making it a 4-year-old public company. It operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. The company is headquartered in Weybridge, United Kingdom. With a market capitalization of £33 billion, HLN is a large established company.
HLN trades on the London Stock Exchange and is classified as a large-cap-cap stock with a market capitalization of approximately £33 billion.
Key Statistics
- Current Price
- £374.80
- Market Cap
- £33.39B
- 52-Week High
- £419.50
- 52-Week Low
- £274.40
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
HLN Investment Performance
HLN has declined 0.0% year-to-date in 2026. Since its IPO in 2022, a £1,000 investment would now be worth £1,146.
£1,000 Invested in Haleon plc (HLN)
How much would £1,000 invested in HLN be worth today?
What would £1,000 invested in HLN 1 year ago be worth today?
A £1,000 investment in Haleon plc (HLN) in 2025 would be worth £993 as of March 2026, representing a -0.7% total return.
What would £1,000 invested in HLN 3 years ago be worth today?
A £1,000 investment in Haleon plc (HLN) in 2023 would be worth £1,146 as of March 2026, representing a +14.6% total return.
What would £1,000 invested in HLN at IPO be worth today?
A £1,000 investment in Haleon plc (HLN) at IPO would be worth £1,146 as of March 2026, representing a +14.6% total return.
Monthly Returns Heatmap
Over the past 3+ years (44 months), Haleon plc (HLN) has averaged a monthly return of +0.73% with a median return of +0.51%. The stock had 25 positive months (57%) and 19 negative months (43%). The best month in HLN's history was December 2022 with a +15.2% return, while the worst was August 2022 at -11.3%. Historically, February tends to be the strongest month (averaging +3.9%), and June the weakest (-3.0%).
HLN's longest winning streak was 5 consecutive months of gains, while its longest losing streak was 2 consecutive months of losses. The best full year was 2024 with a cumulative return of +17.1%, and the worst was 2023 at -0.5%.
Annual Returns
Over 4 years of trading history, Haleon plc (HLN) has delivered an average annual return of +3.74% with a median return of -0.34%. The compound annual growth rate (CAGR) is +3.45%. The stock posted gains in 2 years (50%) and losses in 2 years (50%).
HLN's best year was 2024 with a +17.35% gain, while the worst was 2023 at -1.73%. The longest streak of consecutive positive years was 1, and the longest losing streak was 1 years. HLN achieved double-digit gains (10%+) in 1 years.
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | +0.00% | £374.80 | £374.80 |
| 2025 | -0.67% | £377.33 | £374.80 |
| 2024 | +17.35% | £321.53 | £377.33 |
| 2023 | -1.73% | £327.19 | £321.53 |
HLN Investment Analysis: Valuation, Risk & Dividends
Key factors to consider when evaluating Haleon plc as an investment
Valuation
HLN currently trades at a trailing P/E ratio of 19.7, which is considered moderate relative to the broader market. The forward P/E of 16.6 suggests analysts expect earnings to be lower in the coming year. The price-to-book ratio stands at 202.9. The price-to-sales ratio is 3.0.
Dividends
Haleon plc pays a dividend to shareholders with a current yield of 1.89%. This translates to £0.07 per share annually. The payout ratio of 37% indicates sustainable dividend coverage.
Risk & Volatility
HLN has a beta of 0.25, indicating it is less volatile than the overall market. The stock's 52-week range is £274.40 to £419.50, and it currently trades in the upper half of its 52-week range.
Analyst Ratings
Based on 16 analyst opinions, HLN has a consensus "buy" rating. The average price target of £426.56 suggests 13.8% upside from current levels.
Frequently Asked Questions: HLN
What sector is HLN in? ▼
HLN operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. This sector includes pharmaceutical companies, biotechnology firms, medical device manufacturers, and healthcare providers.
How has HLN performed historically? ▼
Over 4 years of trading history, HLN has posted gains in 2 years (50% of the time). The best year was 2024 with a +17.4% return. Past performance does not guarantee future results.
How can I invest in HLN? ▼
You can invest in HLN through any brokerage account that offers access to the London Stock Exchange. Popular options include commission-free brokers like Fidelity, Charles Schwab, or Robinhood (US), or international brokers like Interactive Brokers. You can buy individual shares or invest through ETFs that hold HLN.
Does HLN pay dividends? ▼
Haleon plc pays a dividend to shareholders with a current yield of 1.89%. This translates to £0.07 per share annually. The payout ratio of 37% indicates sustainable dividend coverage.
What does Haleon plc do? ▼
Haleon plc is a Drug Manufacturers - Specialty & Generic company operating in the Healthcare sector. The company is headquartered in Weybridge, United Kingdom.
What sector is HLN in? ▼
HLN operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
When did HLN go public? ▼
Haleon plc went public in 2022, making it a 4-year-old public company as of 2026.
What is HLN's 3-year return? ▼
Over the past 3 years, HLN has returned 14.6%. A £1,000 investment would have grown to £1,146.
How much would £1,000 invested in HLN at IPO be worth today? ▼
If you invested £1,000 in HLN at its IPO in 2022, it would be worth approximately £1,146 today, a 14.6% return over 4 years.
Does HLN pay dividends? ▼
Yes, Haleon plc pays a dividend with a current yield of 1.89%, which is £0.07 per share annually.
What is HLN's market cap? ▼
Haleon plc has a market capitalization of £33 billion, classifying it as a large-cap company.
What is HLN's P/E ratio? ▼
HLN has a trailing P/E ratio of 19.7 and a forward P/E of 16.6, which measures how much investors are paying per dollar of earnings.
Is HLN a buy, hold, or sell? ▼
Based on 16 opinions, HLN has a consensus "buy" rating. The average price target is £426.56.
Last updated: 3/15/2026